Combination mRNA cancer vaccine and Keytruda sustains recurrence-free survival at five years
Metastatic melanoma cells – Image Credit National Cancer Institute CANCER DIGEST – Jan. 24, 2026 – When a personalized mRNA cancer vaccine is added to an immunotherapy for the treatment of advanced melanoma, more patients survived without recurrence than those treated with pembrolizumab (Keytruda®) alone, the five-year updated results of a clinical trial show. The KEYNOTE-942 ongoing clinical trial ( NCT03897881 ) compares the effectiveness of treatment of patients with stage
Keytruda® cuts distant spread in a rare aggressive skin cancer
Patients with a rare skin cancer who received an immunotherapy drug after surgery had a 42 percent lower risk of the cancer spreading to other parts of the body.
COVID-19 vaccine may have boosted survival in advanced lung cancer patients
Lung cancer patients who received COVID-19 vaccination survived nearly twice as long as similar patients who did not get the vaccine, a new observational study shows.
Engineered T cells targeting solid tumors show promising results in early patient trial
The IMA203 treatment uses T cells engineered to target the PRAME peptide, which is almost exclusively produced by solid tumors and not...
Danish study finds link between tattoos and lymphoma and skin cancer risk
CANCER DIGEST – March 8, 2025 – When most people get a tattoo, their health concerns center almost entirely on cleanliness and risk of...
Melanoma drug reduces disfiguring surgery for basal cell cancer
A drug, already approved for treating superficial melanomas, injected into basal cell tumors reduces surgery and scarring
